HEART OF AUSTRALIA RESEARCH INSTITUTE
Clinical Trials
Though there is more being done today to bring greater access to healthcare services in rural, remote, and First Nations communities, Australians living in these areas are often still excluded from participating in clinical trials due to a number of barriers such as distance, cultural differences, geographic isolation, and workforce capacity.
In 2024 Heart of Australia launched the Heart of Australia Research Institute (HARI) to help facilitate the inclusion of country patients into clinical trials, giving them an equal chance of accessing innovative treatments and solutions not yet available to the general public.
HARI is currently helping to deliver four ongoing clinical trials in rural Queensland with the support of our partners and research team members.
We currently have eleven active trials, and seven are open for screening.
If you are a healthcare provider interested in finding out more about clinical trials, please email research@heartofaustralia.com
HARI Partners
Major Partner
Alliance Member
Trials Screening for Participants
MOVE-Lp(a)
History of heart disease/stroke or at risk of heart disease/stroke
This trial will investigate the effect of lipoprotein (a) {Lp(a)} lowering treatment on the reduction of major cardiovascular events in patients with elevated Lp(a) levels.
HF Polaris
Heart failure with obesity
This trial will assess morbidity and mortality on patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) following a once monthly subcutaneous injection.
AMAZE 1
Obesity
This trial is a Phase III study to evaluate the efficacy and safety of a once-weekly injection in participants with obesity.
AMAZE 5/6
Obesity with knee osteoarthritis
This trial is a Phase III study to evaluate the efficacy and safety of a once-weekly injection in participants with obesity & knee osteoarthritis.
EasiProtkt
Hypertension with Type 2 diabetes & cardiovascular disease
This trial is a Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the investigational product compared with placebo in participants with type 2 diabetes, hypertension and established cardiovascular disease.
Zenith
Hypertension
This trial is a Phase III double-blind, placebo-controlled study to evaluate the efficacy of a 6 monthly dose of the investigational product in addition to standard of care in reducing major adverse cardiovascular Events. Enrolling adult patients with hypertension, currently taking at least 2 anti-hypertensive medications.
Trials Currently Being Conducted (Screening Closed)
Eli Lilly EZEF
Reduction of major adverse cardiovascular events in adults with Atherosclerotic Cardiovascular Disease.
Novo Nordisk Hermes
Patients with heart failure, with preserved/mildly reduced LV function.
Boehringer Ingelheim Airtivity
A study to find out whether a daily oral medication helps people with bronchiectasis.
Novo Nordisk CKD Trial
To demonstrate and characterise the dose–response relationship of a once-weekly injection to reduce kidney damage in people living with chronic kidney disease.
HARI Team Members
Investigators
Dr Rolf Gomes
BE, MBBS, FRACP
Principal Investigator
General Cardiologist
Dr Farzad Bashirzadeh
FRACP, MD, MSM
Principal Investigator
Respiratory (Thoracic) Specialist
Dr Richard Baer
BPharm, MBBS(Hons), MPH&TM, FRACP
Principal Investigator
Nephrologist
Assoc. Prof Karam Kostner
MD, PhD, FRACP, FCSANZ
Sub-Investigator
Cardiologist and Lipidologist
Dr Alexander Dashwood
BM, BSc, FRACP, MRCP (UK)
Sub-Investigator
General Cardiologist & Cardiac Electrophysiologist
Dr Elizabeth Clarkson
MBBS QLD, FACRRM, FRACGP, FARGP
Sub-Investigator
Rural Generalist (GP)
Team Members
Caroline Herbert
Clinical Trials Coordinator
Tiki Baker-Pearson
Clinical Trials Coordinator